Canton Strategic Holdings, Inc.
Canton Strategic Holdings, Inc. (CNTN): 3 pipeline candidates · ~17 mo cash runway. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
16.5 months
D/E 0.24 · 267% dilution
Lead: Preclinical
3 candidates
N/A
0 buys · 8 sells (180d)
A transparent, data-derived signal for Canton Strategic Holdings, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$247.1M
Cash
$41.5M
Quarterly Burn
$7.6M
Runway
16.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| gv104 | Preclinical |
| pria-kit priapism kit s.s | — |
| pria-kit priapism kit s.s | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
37
Total value held
$30.6M
| Holder | Shares | Value |
|---|---|---|
| ark investment management llc | 3,695,084 | $12.1M |
| vanguard capital management llc | 905,360 | $3.0M |
| blackrock, inc. | 765,829 | $2.5M |
| amova asset management americas, inc. | 728,167 | $2.4M |
| renaissance technologies llc | 562,000 | $1.8M |
| geode capital management, llc | 440,112 | $1.4M |
| millennium management llc | 359,183 | $1.2M |
| feynman point asset management llc | 350,568 | $1.1M |
| bienville capital management, llc | 216,802 | $709K |
| vanguard fiduciary trust co | 211,445 | $691K |
Showing top 10 of 37 institutional holders of Canton Strategic Holdings, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Canton Strategic Holdings, Inc.'s pipeline?
Canton Strategic Holdings, Inc. (CNTN) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Canton Strategic Holdings, Inc.'s lead drug candidate?
Canton Strategic Holdings, Inc.'s most advanced tracked candidate is gv104 (Preclinical) for prophylactic protection against synthetic opioid exposure in military and first responder populations.
What is Canton Strategic Holdings, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Canton Strategic Holdings, Inc. has approximately 16.5 months of cash runway.
What is Canton Strategic Holdings, Inc.'s market capitalization?
Canton Strategic Holdings, Inc.'s market capitalization is approximately $247.1M.
Who is the CEO of Canton Strategic Holdings, Inc.?
Mr. Mark Wendland is the chief executive officer of Canton Strategic Holdings, Inc. (CNTN).
Get the full picture on Canton Strategic Holdings, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.